Cargando…

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study

BACKGROUND: Anlotinib is a multi-target anti-angiogenic agent. The retrospective study was conducted to evaluate the safety and effectiveness of anlotinib as monotherapy or combination therapy for the treatment of recurrent high-grade gliomas. METHODS: In this retrospective study, patients with recu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Jun, Yin, Wenya, Zheng, Linlin, Li, Yimin, Luo, Cheng, Zhang, Shuo, Duan, Lei, Zhou, Hang, Cheng, Kai, Lang, Jinyi, Xu, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331188/ https://www.ncbi.nlm.nih.gov/pubmed/37435019 http://dx.doi.org/10.1177/11795549231175714

Ejemplares similares

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study
por: Li, Xiaoyuan, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
por: Yao, Weitao, et al.
Publicado: (2022)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
por: Jin, Nan, et al.
Publicado: (2022)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Platinum-based Chemotherapy in Recurrent High-grade Glioma Patients: Retrospective Study
por: Roci, Ermir, et al.
Publicado: (2014)

The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia
por: Yang, Linlin, et al.
Publicado: (2023)

UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib
por: Shi, Yingying, et al.
Publicado: (2023)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
por: Cheng, Ke, et al.
Publicado: (2022)

Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report
por: Tao, Junyue, et al.
Publicado: (2022)

Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma
por: Luo, Cheng, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas
por: Gregucci, Fabiana, et al.
Publicado: (2022)

Integrated mRNAseq and microRNAseq data analysis for grade III gliomas
por: Dai, Junqiang, et al.
Publicado: (2017)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity
por: Treiber, Hannes, et al.
Publicado: (2022)

Re-irradiation alternatives for recurrent high-grade glioma
por: Dong, Yuanli, et al.
Publicado: (2016)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

Identification of molecular subtypes and a risk model based on inflammation-related genes in patients with low grade glioma
por: Long, Cheng, et al.
Publicado: (2023)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma
por: Eberle, Fabian, et al.
Publicado: (2020)

Decisional needs of patients with recurrent high-grade glioma and their families
por: Sorensen von Essen, Helle, et al.
Publicado: (2022)

Postoperative functional status in patients with supratentorial superficial low-grade glioma
por: Zhang, Ji, et al.
Publicado: (2017)

Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review
por: Feng, Yiping, et al.
Publicado: (2022)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review
por: Lv, Yajuan, et al.
Publicado: (2019)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t1j9gtkqm16iuqsa95ith93hlh